Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shionogi Sets Up In Europe, To Develop Pipeline Before The "Crestor Cliff"

This article was originally published in The Pink Sheet Daily

Executive Summary

Anticipating the loss of royalties from Crestor in the next five years, Japanese innovator Shionogi continues its globalization process with a U.K. headquarters to pursue development of its late-stage research pipeline in Europe.

You may also be interested in...



Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results

Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.

Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning

TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)

Hit By Earthquake and U.S. Restructuring, Shionogi Looks To Regroup In Time For Crestor Loss

TOKYO - Shionogi & Co. Ltd. is fighting a two-front battle, recovery from the March 2011 earthquake and tsunami in Northern Japan and restructuring of its U.S. acquisition. The company formulated a mid-term plan to address ways to buffer the September 2016 patent loss of Crestor (rosuvastatin), by far the company's most important drug, but setbacks in the U.S. raise doubts about the company's ability to counter the patent cliff

Topics

Related Companies

UsernamePublicRestriction

Register

PS074481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel